

## USA, California, Los Angeles (1993-2012)

	Number of cases							Percentage				Incidence rates per million person-years						MV % 0-19	DCO % 0-19			
	Age group							0-14		0-19		Age-specific					Cumulative					
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14			ASR	0-19	0-14
<b>I LEUKAEMIA</b>	146	1106	671	555	529	2478	3007	37.9	100.0	32.2	100.0	50.1	95.1	47.6	39.2	38.2	60.0	55.1	864	1055	99.5	0.1
a. Lymphoid	65	958	569	401	329	1993	2322	30.5	80.4	24.9	77.2	22.3	82.3	40.3	28.3	23.8	48.4	42.9	695	814	99.8	0.0
b. Acute myeloid	60	120	81	118	138	379	517	5.8	15.3	5.5	17.2	20.6	10.3	5.7	8.3	10.0	9.1	9.3	132	182	99.6	0.0
c. CMD	9	5	9	25	44	48	92	0.7	1.9	1.0	3.1	3.1	0.4	0.6	1.8	3.2	1.1	1.6	17	33	92.4	0.0
d. MDS & other	6	11	3	5	7	25	32	0.4	1.0	0.3	1.1	2.1	0.9	0.2	0.4	0.5	0.6	0.6	9	11	96.9	0.0
e. Unspecified	6	12	9	6	11	33	44	0.5	1.3	0.5	1.5	2.1	1.0	0.6	0.4	0.8	0.8	0.8	11	15	95.5	2.3
<b>II LYMPHOMA &amp; RELATED</b>	30	118	194	339	572	681	1253	10.4	100.0	13.4	100.0	10.3	10.1	13.8	23.9	41.3	15.3	21.2	239	446	99.0	0.0
a. Hodgkin	0	16	74	170	355	260	615	4.0	38.2	6.6	49.1	-	1.4	5.2	12.0	25.6	5.6	10.1	92	220	99.8	0.0
b. Non-Hodgkin except BL	7	44	71	115	182	237	419	3.6	34.8	4.5	33.4	2.4	3.8	5.0	8.1	13.1	5.3	7.1	83	149	99.0	0.0
c. Burkitt (BL)	1	25	29	41	23	96	119	1.5	14.1	1.3	9.5	0.3	2.1	2.1	2.9	1.7	2.2	2.1	34	42	100.0	0.0
d. Lymphoreticular	22	29	16	7	5	74	79	1.1	10.9	0.8	6.3	7.5	2.5	1.1	0.5	0.4	1.9	1.5	26	27	100.0	0.0
e. Unspecified	0	4	4	6	7	14	21	0.2	2.1	0.2	1.7	-	0.3	0.3	0.4	0.5	0.3	0.4	5	7	66.7	0.0
<b>III CNS NEOPLASMS</b>	81	388	413	294	247	1176	1423	18.0	100.0	15.2	100.0	27.8	33.3	29.3	20.8	17.8	27.9	25.7	411	501	90.2	0.3
a. Ependymoma	14	51	35	11	28	111	139	1.7	9.4	1.5	9.8	4.8	4.4	2.5	0.8	2.0	2.8	2.6	39	49	100.0	0.0
b. Astrocytoma	27	152	179	160	135	518	653	7.9	44.0	7.0	45.9	9.3	13.1	12.7	11.3	9.8	12.1	11.6	181	230	96.3	0.5
c. CNS embryonal	30	131	112	61	40	334	374	5.1	28.4	4.0	26.3	10.3	11.3	7.9	4.3	2.9	8.1	6.9	117	131	99.2	0.0
d. Other gliomas	6	40	80	54	38	180	218	2.8	15.3	2.3	15.3	2.1	3.4	5.7	3.8	2.7	4.2	3.8	63	77	49.5	0.0
e. Other specified	3	10	6	6	5	25	30	0.4	2.1	0.3	2.1	1.0	0.9	0.4	0.4	0.4	0.6	0.6	9	11	100.0	0.0
f. Unspecified CNS	1	4	1	2	1	8	9	0.1	0.7	0.1	0.6	0.3	0.3	0.1	0.1	0.1	0.2	0.2	3	3	66.7	11.1
<b>IV NEUROBLASTOMA</b>	101	171	44	24	8	340	348	5.2	100.0	3.7	100.0	34.6	14.7	3.1	1.7	0.6	8.7	6.9	118	120	99.4	0.0
a. (Ganglio)neuroblastoma	101	171	40	18	1	330	331	5.0	97.1	3.5	95.1	34.6	14.7	2.8	1.3	0.1	8.5	6.6	114	114	99.4	0.0
b. Peripheral nervous	0	0	4	6	7	10	17	0.2	2.9	0.2	4.9	-	-	0.3	0.4	0.5	0.2	0.3	4	6	100.0	0.0
<b>V RETINOBLASTOMA</b>	85	141	7	0	0	233	233	3.6	100.0	2.5	100.0	29.1	12.1	0.5	-	-	6.2	4.8	80	80	85.4	0.0
<b>VI RENAL TUMOURS</b>	51	195	67	11	17	324	341	5.0	100.0	3.7	100.0	17.5	16.8	4.7	0.8	1.2	8.3	6.7	112	118	99.7	0.0
a. Nephroblastoma	50	195	66	7	3	318	321	4.9	98.1	3.4	94.1	17.1	16.8	4.7	0.5	0.2	8.2	6.4	110	111	99.7	0.0
b. Renal carcinoma	1	0	1	4	14	6	20	0.1	1.9	0.2	5.9	0.3	-	0.1	0.3	1.0	0.1	0.3	2	7	100.0	0.0
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>VII HEPATIC TUMOURS</b>	42	66	6	16	19	130	149	2.0	100.0	1.6	100.0	14.4	5.7	0.4	1.1	1.4	3.3	2.9	45	52	98.0	0.0
a. Hepatoblastoma	41	64	3	8	1	116	117	1.8	89.2	1.3	78.5	14.1	5.5	0.2	0.6	0.1	3.0	2.4	40	40	98.3	0.0
b. Hepatic carcinoma	1	2	3	8	18	14	32	0.2	10.8	0.3	21.5	0.3	0.2	0.2	0.6	1.3	0.3	0.5	5	11	96.9	0.0
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>VIII BONE TUMOURS</b>	3	19	63	155	201	240	441	3.7	100.0	4.7	100.0	1.0	1.6	4.5	10.9	14.5	5.2	7.3	85	157	99.8	0.0
a. Osteosarcoma	0	4	44	102	132	150	282	2.3	62.5	3.0	63.9	-	0.3	3.1	7.2	9.5	3.2	4.6	53	101	100.0	0.0
b. Chondrosarcoma	0	0	1	9	7	10	17	0.2	4.2	0.2	3.9	-	-	0.1	0.6	0.5	0.2	0.3	4	6	100.0	0.0
c. Ewing & related	0	13	13	41	48	67	115	1.0	27.9	1.2	26.1	-	1.1	0.9	2.9	3.5	1.5	1.9	24	41	99.1	0.0
d. Other specified	3	2	4	3	14	12	26	0.2	5.0	0.3	5.9	1.0	0.2	0.3	0.2	1.0	0.3	0.4	4	9	100.0	0.0
e. Unspecified	0	0	1	0	0	1	1	0.0	0.4	0.0	0.2	-	-	0.1	-	-	0.0	0.0	0	0	100.0	0.0
<b>IX SOFT TISSUE SARCOMA</b>	47	100	116	155	210	418	628	6.4	100.0	6.7	100.0	16.1	8.6	8.2	10.9	15.2	9.7	11.0	146	222	99.8	0.0
a. Rhabdomyosarcoma	14	68	64	43	40	189	229	2.9	45.2	2.5	36.5	4.8	5.8	4.5	3.0	2.9	4.5	4.2	66	80	100.0	0.0
b. Fibrosarcoma	13	8	8	22	32	51	83	0.8	12.2	0.9	13.2	4.5	0.7	0.6	1.6	2.3	1.2	1.4	18	29	100.0	0.0
c. Kaposi sarcoma	1	0	0	1	2	2	4	0.0	0.5	0.0	0.6	0.3	-	-	0.1	0.1	0.0	0.1	1	1	100.0	0.0
d. Other specified	14	19	39	69	121	141	262	2.2	33.7	2.8	41.7	4.8	1.6	2.8	4.9	8.7	3.2	4.4	50	93	100.0	0.0
e. Unspecified	5	5	5	20	15	35	50	0.5	8.4	0.5	8.0	1.7	0.4	0.4	1.4	1.1	0.8	0.9	12	18	98.0	0.0
<b>X GERM CELL TUMOURS</b>	66	47	45	134	473	292	765	4.5	100.0	8.2	100.0	22.6	4.0	3.2	9.5	34.2	6.8	12.9	102	273	98.7	0.1
a. CNS germ cell	6	3	19	53	40	81	121	1.2	27.7	1.3	15.8	2.1	0.3	1.3	3.7	2.9	1.8	2.0	29	43	95.0	0.0
b. Other extragonadal	39	16	3	6	29	64	93	1.0	21.9	1.0	12.2	13.4	1.4	0.2	0.4	2.1	1.7	1.8	22	33	97.8	1.1
c. Gonadal germ cell	20	28	21	68	373	137	510	2.1	46.9	5.5	66.7	6.9	2.4	1.5	4.8	26.9	3.2	8.5	48	183	99.8	0.0
d. Gonadal carcinoma	0	0	0	4	27	4	31	0.1	1.4	0.3	4.1	-	-	-	0.3	2.0	0.1	0.5	1	11	100.0	0.0
e. Unspecified gonadal	1	0	2	3	4	6	10	0.1	2.1	0.1	1.3	0.3	-	0.1	0.2	0.3	0.1	0.2	2	4	90.0	0.0
<b>XI CARCINOMA &amp; MELANOMA</b>	2	13	45	156	497	216	713	3.3	100.0	7.6	100.0	0.7	1.1	3.2	11.0	35.9	4.6	11.7	76	256	99.4	0.1
a. Adrenocortical	0	3	1	3	1	7	8	0.1	3.2	0.1	1.1	-	0.3	0.1	0.2	0.1	0.2	0.1	2	3	100.0	0.0
b. Thyroid	0	0	19	65	231	84	315	1.3	38.9	3.4	44.2	-	-	1.3	4.6	16.7	1.8	5.1	30	113	99.7	0.3
c. Nasopharyngeal	0	0	0	12	18	12	30	0.2	5.6	0.3	4.2	-	-	-	0.8	1.3	0.2	0.5	4	11	100.0	0.0
d. Melanoma	1	8	17	23	113	49	162	0.7	22.7	1.7	22.7	0.3	0.7	1.2	1.6	8.2	1.1	2.7	17	58	98.8	0.0
e. Skin carcinoma	0	0	0	4	4	4	8	0.1	1.9	0.1	1.1	-	-	-	0.3	0.3	0.1	0.1	1	3	100.0	0.0
f. Other & unspecified	1	2	8	49	130	60	190	0.9	27.8	2.0	26.6	0.3	0.2	0.6	3.5	9.4	1.3	3.1	21	68	99.5	0.0
<b>XII OTHER &amp; UNSPECIFIED</b>	2	5	4	6	15	17	32	0.3	100.0	0.3	100.0	0.7	0.4	0.3	0.4	1.1	0.4	0.6	6	11	90.6	3.1
a. Other specified	2	3	2	4	8	11	19	0.2	64.7	0.2	59.4	0.7	0.3	0.1	0.3	0.6	0.3	0.3	4	7	100.0	0.0
b. Other unspecified	0	2	2	2	7	6	13	0.1	35.3	0.1	40.6	-	0.2	0.1	0.1	0.5	0.1	0.2	2	5	76.9	7.7
<b>TOTAL</b>	656	2369	1675	1845	2788	6545	9333	100.0	100.0	100.0	100.0	224.9	203.6	118.7	130.3	201.4	156.6	166.7	2284	3291	97.6	0.1

Please consult the quality indicators for this registry

### USA, California, Los Angeles (1993-2012)

	Males								M/F ratio		Females									
	0	1-4	Number of cases in age groups			ASR per million		0-14	0-19	0-14	0-19	0	1-4	Number of cases in age groups			ASR per million			
			5-9	10-14	15-19	0-14	0-19	0-14	0-19					5-9	10-14	15-19	0-14	0-19	0-14	0-19
<b>I LEUKAEMIA</b>	76	613	363	320	329	<b>1372</b>	<b>1701</b>	<b>64.9</b>	<b>60.7</b>	1.2	1.3	70	493	308	235	200	<b>1106</b>	<b>1306</b>	<b>54.9</b>	<b>49.3</b>
a. Lymphoid	34	533	311	226	227	<b>1104</b>	<b>1331</b>	<b>52.5</b>	<b>47.8</b>	1.2	1.3	31	425	258	175	102	<b>889</b>	<b>991</b>	<b>44.2</b>	<b>37.7</b>
b. Acute myeloid	31	63	39	73	69	<b>206</b>	<b>275</b>	<b>9.6</b>	<b>9.6</b>	1.2	1.1	29	57	42	45	69	<b>173</b>	<b>242</b>	<b>8.5</b>	<b>8.9</b>
c. CMD	4	4	6	16	24	<b>30</b>	<b>54</b>	<b>1.3</b>	<b>1.8</b>	1.7	1.4	5	1	3	9	20	<b>18</b>	<b>38</b>	<b>0.8</b>	<b>1.3</b>
d. MDS & other	4	5	0	2	2	<b>11</b>	<b>13</b>	<b>0.5</b>	<b>0.5</b>	0.8	0.7	2	6	3	3	5	<b>14</b>	<b>19</b>	<b>0.7</b>	<b>0.7</b>
e. Unspecified	3	8	7	3	7	<b>21</b>	<b>28</b>	<b>1.0</b>	<b>1.0</b>	1.8	1.8	3	4	2	3	4	<b>12</b>	<b>16</b>	<b>0.6</b>	<b>0.6</b>
<b>II LYMPHOMA &amp; RELATED</b>	16	75	139	215	314	<b>445</b>	<b>759</b>	<b>19.6</b>	<b>25.1</b>	1.9	1.5	14	43	55	124	258	<b>236</b>	<b>494</b>	<b>10.9</b>	<b>17.1</b>
a. Hodgkin	0	12	51	101	176	<b>164</b>	<b>340</b>	<b>7.0</b>	<b>10.9</b>	1.7	1.2	0	4	23	69	179	<b>96</b>	<b>275</b>	<b>4.2</b>	<b>9.2</b>
b. Non-Hodgkin except BL	4	26	52	73	114	<b>155</b>	<b>269</b>	<b>6.8</b>	<b>8.9</b>	1.9	1.8	3	18	19	42	68	<b>82</b>	<b>150</b>	<b>3.8</b>	<b>5.2</b>
c. Burkitt (BL)	1	19	24	32	18	<b>76</b>	<b>94</b>	<b>3.4</b>	<b>3.2</b>	3.8	3.8	0	6	5	9	5	<b>20</b>	<b>25</b>	<b>0.9</b>	<b>0.9</b>
d. Lymphoreticular	11	16	9	5	2	<b>41</b>	<b>43</b>	<b>2.0</b>	<b>1.6</b>	1.2	1.2	11	13	7	2	3	<b>33</b>	<b>36</b>	<b>1.7</b>	<b>1.4</b>
e. Unspecified	0	2	3	4	4	<b>9</b>	<b>13</b>	<b>0.4</b>	<b>0.4</b>	1.8	1.6	0	2	1	2	3	<b>5</b>	<b>8</b>	<b>0.2</b>	<b>0.3</b>
<b>III CNS NEOPLASMS</b>	39	223	215	155	148	<b>632</b>	<b>780</b>	<b>29.5</b>	<b>27.5</b>	1.2	1.2	42	165	198	139	99	<b>544</b>	<b>643</b>	<b>26.4</b>	<b>23.8</b>
a. Ependymoma	8	33	20	6	20	<b>67</b>	<b>87</b>	<b>3.3</b>	<b>3.2</b>	1.5	1.7	6	18	15	5	8	<b>44</b>	<b>52</b>	<b>2.2</b>	<b>2.0</b>
b. Astrocytoma	13	82	89	84	82	<b>268</b>	<b>350</b>	<b>12.3</b>	<b>12.1</b>	1.1	1.2	14	70	90	76	53	<b>250</b>	<b>303</b>	<b>12.0</b>	<b>11.1</b>
c. CNS embryonal	13	80	62	36	23	<b>191</b>	<b>214</b>	<b>9.1</b>	<b>7.7</b>	1.3	1.3	17	51	50	25	17	<b>143</b>	<b>160</b>	<b>7.1</b>	<b>6.1</b>
d. Other gliomas	2	20	39	26	19	<b>87</b>	<b>106</b>	<b>3.9</b>	<b>3.6</b>	0.9	0.9	4	20	41	28	19	<b>93</b>	<b>112</b>	<b>4.4</b>	<b>4.0</b>
e. Other specified	3	5	4	2	4	<b>14</b>	<b>18</b>	<b>0.7</b>	<b>0.6</b>	1.3	1.5	0	5	2	4	1	<b>11</b>	<b>12</b>	<b>0.5</b>	<b>0.4</b>
f. Unspecified CNS	0	3	1	1	0	<b>5</b>	<b>5</b>	<b>0.2</b>	<b>0.2</b>	1.7	1.3	1	1	0	1	1	<b>3</b>	<b>4</b>	<b>0.2</b>	<b>0.2</b>
<b>IV NEUROBLASTOMA</b>	59	90	26	7	5	<b>182</b>	<b>187</b>	<b>9.2</b>	<b>7.3</b>	1.2	1.2	42	81	18	17	3	<b>158</b>	<b>161</b>	<b>8.3</b>	<b>6.5</b>
a. (Ganglio)neuroblastoma	59	90	24	7	0	<b>180</b>	<b>180</b>	<b>9.1</b>	<b>7.1</b>	1.2	1.2	42	81	16	11	1	<b>150</b>	<b>151</b>	<b>7.9</b>	<b>6.2</b>
b. Peripheral nervous	0	0	2	0	5	<b>2</b>	<b>7</b>	<b>0.1</b>	<b>0.2</b>	0.3	0.7	0	0	2	6	2	<b>8</b>	<b>10</b>	<b>0.3</b>	<b>0.3</b>
<b>V RETINOBLASTOMA</b>	44	80	3	0	0	<b>127</b>	<b>127</b>	<b>6.6</b>	<b>5.1</b>	1.2	1.2	41	61	4	0	0	<b>106</b>	<b>106</b>	<b>5.7</b>	<b>4.5</b>
<b>VI RENAL TUMOURS</b>	25	78	24	3	8	<b>130</b>	<b>138</b>	<b>6.5</b>	<b>5.3</b>	0.7	0.7	26	117	43	8	9	<b>194</b>	<b>203</b>	<b>10.1</b>	<b>8.2</b>
a. Nephroblastoma	25	78	24	1	1	<b>128</b>	<b>129</b>	<b>6.5</b>	<b>5.0</b>	0.7	0.7	25	117	42	6	2	<b>190</b>	<b>192</b>	<b>10.0</b>	<b>7.8</b>
b. Renal carcinoma	0	0	0	2	7	<b>2</b>	<b>9</b>	<b>0.1</b>	<b>0.3</b>	0.5	0.8	1	0	1	2	7	<b>4</b>	<b>11</b>	<b>0.2</b>	<b>0.4</b>
c. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	-	-	0	0	0	0	0	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>
<b>VII HEPATIC TUMOURS</b>	19	43	4	10	10	<b>76</b>	<b>86</b>	<b>3.8</b>	<b>3.3</b>	1.4	1.4	23	23	2	6	9	<b>54</b>	<b>63</b>	<b>2.9</b>	<b>2.5</b>
a. Hepatoblastoma	19	42	2	5	1	<b>68</b>	<b>69</b>	<b>3.5</b>	<b>2.7</b>	1.4	1.4	22	22	1	3	0	<b>48</b>	<b>48</b>	<b>2.6</b>	<b>2.0</b>
b. Hepatic carcinoma	0	1	2	5	9	<b>8</b>	<b>17</b>	<b>0.3</b>	<b>0.5</b>	1.3	1.1	1	1	1	3	9	<b>6</b>	<b>15</b>	<b>0.3</b>	<b>0.5</b>
c. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>	-	-	0	0	0	0	0	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>
<b>VIII BONE TUMOURS</b>	1	13	32	80	126	<b>126</b>	<b>252</b>	<b>5.4</b>	<b>8.1</b>	1.1	1.3	2	6	31	75	75	<b>114</b>	<b>189</b>	<b>5.0</b>	<b>6.4</b>
a. Osteosarcoma	0	2	20	46	81	<b>68</b>	<b>149</b>	<b>2.8</b>	<b>4.8</b>	0.8	1.1	0	2	24	56	51	<b>82</b>	<b>133</b>	<b>3.6</b>	<b>4.5</b>
b. Chondrosarcoma	0	0	1	8	6	<b>9</b>	<b>15</b>	<b>0.4</b>	<b>0.5</b>	9.0	7.5	0	0	0	1	1	<b>1</b>	<b>2</b>	<b>0.0</b>	<b>0.1</b>
c. Ewing & related	0	10	8	24	33	<b>42</b>	<b>75</b>	<b>1.8</b>	<b>2.5</b>	1.7	1.9	0	3	5	17	15	<b>25</b>	<b>40</b>	<b>1.1</b>	<b>1.4</b>
d. Other specified	1	1	2	2	6	<b>6</b>	<b>12</b>	<b>0.3</b>	<b>0.4</b>	1.0	0.9	2	1	2	1	8	<b>6</b>	<b>14</b>	<b>0.3</b>	<b>0.5</b>
e. Unspecified	0	0	1	0	0	<b>1</b>	<b>1</b>	<b>0.0</b>	<b>0.0</b>	-	-	0	0	0	0	0	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>
<b>IX SOFT TISSUE SARCOMA</b>	23	57	71	86	115	<b>237</b>	<b>352</b>	<b>10.8</b>	<b>12.0</b>	1.3	1.3	24	43	45	69	95	<b>181</b>	<b>276</b>	<b>8.6</b>	<b>9.9</b>
a. Rhabdomyosarcoma	8	42	38	23	29	<b>111</b>	<b>140</b>	<b>5.2</b>	<b>5.0</b>	1.4	1.6	6	26	26	20	11	<b>78</b>	<b>89</b>	<b>3.8</b>	<b>3.3</b>
b. Fibrosarcoma	6	4	5	10	17	<b>25</b>	<b>42</b>	<b>1.1</b>	<b>1.4</b>	1.0	1.0	7	4	3	12	15	<b>26</b>	<b>41</b>	<b>1.2</b>	<b>1.5</b>
c. Kaposi sarcoma	1	0	0	1	2	<b>2</b>	<b>4</b>	<b>0.1</b>	<b>0.1</b>	-	-	0	0	0	0	0	<b>0</b>	<b>0</b>	<b>-</b>	<b>-</b>
d. Other specified	6	8	26	40	57	<b>80</b>	<b>137</b>	<b>3.5</b>	<b>4.5</b>	1.3	1.1	8	11	13	29	64	<b>61</b>	<b>125</b>	<b>2.9</b>	<b>4.4</b>
e. Unspecified	2	3	2	12	10	<b>19</b>	<b>29</b>	<b>0.8</b>	<b>1.0</b>	1.2	1.4	3	2	3	8	5	<b>16</b>	<b>21</b>	<b>0.7</b>	<b>0.7</b>
<b>X GERM CELL TUMOURS</b>	39	29	12	62	337	<b>142</b>	<b>479</b>	<b>6.6</b>	<b>15.7</b>	0.9	1.7	27	18	33	72	136	<b>150</b>	<b>286</b>	<b>7.0</b>	<b>10.0</b>
a. CNS germ cell	2	2	10	42	32	<b>56</b>	<b>88</b>	<b>2.3</b>	<b>2.8</b>	2.2	2.7	4	1	9	11	8	<b>25</b>	<b>33</b>	<b>1.2</b>	<b>1.2</b>
b. Other extragonadal	17	4	1	5	22	<b>27</b>	<b>49</b>	<b>1.3</b>	<b>1.7</b>	0.7	1.1	22	12	2	1	7	<b>37</b>	<b>44</b>	<b>2.0</b>	<b>1.8</b>
c. Gonadal germ cell	20	23	1	15	281	<b>59</b>	<b>340</b>	<b>2.9</b>	<b>11.1</b>	0.8	2.0	0	5	20	53	92	<b>78</b>	<b>170</b>	<b>3.4</b>	<b>5.7</b>
d. Gonadal carcinoma	0	0	0	0	1	<b>0</b>	<b>1</b>	<b>-</b>	<b>0.0</b>	0.0	0.0	0	0	0	4	26	<b>4</b>	<b>30</b>	<b>0.2</b>	<b>1.0</b>
e. Unspecified gonadal	0	0	0	0	1	<b>0</b>	<b>1</b>	<b>-</b>	<b>0.0</b>	0.0	0.1	1	0	2	3	3	<b>6</b>	<b>9</b>	<b>0.3</b>	<b>0.3</b>
<b>XI CARCINOMA &amp; MELANOMA</b>	1	6	14	54	165	<b>75</b>	<b>240</b>	<b>3.2</b>	<b>7.7</b>	0.5	0.5	1	7	31	102	332	<b>141</b>	<b>473</b>	<b>6.2</b>	<b>15.9</b>
a. Adrenocortical	0	2	1	0	0	<b>3</b>	<b>3</b>	<b>0.1</b>	<b>0.1</b>	0.8	0.6	0	1	0	3	1	<b>4</b>	<b>5</b>	<b>0.2</b>	<b>0.2</b>
b. Thyroid	0	0	2	10	45	<b>12</b>	<b>57</b>	<b>0.5</b>	<b>1.8</b>	0.2	0.2	0	0	17	55	186	<b>72</b>	<b>258</b>	<b>3.1</b>	<b>8.6</b>
c. Nasopharyngeal	0	0	0	11	13	<b>11</b>	<b>24</b>	<b>0.4</b>	<b>0.8</b>	11.0	4.0	0	0	0	1	5	<b>1</b>	<b>6</b>	<b>0.0</b>	<b>0.2</b>
d. Melanoma	0	4	8	12	55	<b>24</b>	<b>79</b>	<b>1.0</b>	<b>2.5</b>	1.0	1.0	1	4	9	11	58	<b>25</b>	<b>83</b>	<b>1.2</b>	<b>2.8</b>
e. Skin carcinoma	0	0	0	3	2	<b>3</b>	<b>5</b>	<b>0.1</b>	<b>0.2</b>	3.0	1.7	0	0	0	1	2	<b>1</b>	<b>3</b>	<b>0.0</b>	<b>0.1</b>
f. Other & unspecified	1	0	3	18	50	<b>22</b>	<b>72</b>	<b>0.9</b>												

## USA, California, Los Angeles (1993-2012)

	Age group	Males	Females
Person-years	0	1 494 437	1 422 066
	1-4	5 951 234	5 684 227
	5-9	7 211 669	6 896 269
	10-14	7 236 889	6 925 503
	15-19	7 128 336	6 713 362
Total	0-14	21 894 229	20 928 065
	0-19	29 022 565	27 641 427
Average annual population	0-14	1 094 711	1 046 403
	0-19	1 451 128	1 382 071

Please consult the quality indicators for this registry